Table 3.

Univariate analysis in terms of OS (overall survival) and EFI (event free survival) with correction for competing risks and on the total population

Variable		SHR	95% C.I.	p value
EFI
NPM1	Continuous	0.99	0.98–1.00	0.147
NPM1 nucleolus	No	1
	Yes	1.83	0.79–4.27	0.161
NPM1 with cut-off	> 50%	1
	≤50%	1.43	0.69–3.02	0.334
nAPE1	Continuous	0.99	0.98–1.00	0.344
cAPE1	Continuous	1.01	0.99–1.02	0.149
Tumor size	1	1
	2	1.35	0.58–3.14	0.491
	3 or 4	3.48	0.79–15.44	0.100
Nodal status	Negative	1
	Positive	2.05	0.92–4.58	0.079
Neo/Adj Anthracyclines	No	1
	Yes	1.06	0.47–2.39	0.886
Neo/Adj Taxanes	No	1
	Yes	0.82	0.39–1.69	0.585
OS		HR	95% C.I.	p value
NPM1 nucleolus	No	1
	Yes	1.37	0.59–3.20	0.464
NPM1 with cut-off	> 50%	1
	≤50%	1.25	0.61–2.57	0.541
nAPE1	Continuous	1	0.99–1.01	0.767
cAPE1	Continuous	1	0.99–1.01	0.553
Tumor size	1	1
	2	1.73	0.73–4.11	0.214
	3 or 4	12.59	4.30–36.84	< 0.001
Nodal status	Negative	1
	Positive	1.47	0.68–3.17	0.328
Neo/Adj Anthracyclines	No	1
	Yes	0.45	0.22–0.91	0.026
Neo/Adj Taxanes	No	1
	Yes	0.50	0.24–1.02	0.055

Tumor size was confirmed as the most important prognostic factor. nAPE1 (nuclear APE1), cAPE1 (cytoplasmic APE1) NPM1 (NPM1^low vs NPM1^high), HR (hazard ratio), SHR (subdistribution hazard ratio)